Table 2.
Characteristics of HIV‐infected participants—ACHIEvA study 2015
| Characteristic | N = 577 |
|---|---|
| Taking ART, No. (%) | 528 (91.5) |
| HIV, not initiated ART | 24 (4.2) |
| Previously undiagnosed, No. (%) | 25 (4.3) |
| Follow‐up duration before ART initiation, median (IQR), mo | 4 .3 (1.4‐24.9) |
| Follow‐up duration after ART initiation, median (IQR), y | 4.8 (2.6‐7.6) |
| Age at ART initiation, median (IQR), y | 40 (37‐45) |
| Systolic BP at ART initiation, mean (SD) | 116 (18) |
| Diastolic BP at ART initiation, mean (SD) | 73 (10) |
| Body mass index at ART initiation, mean (SD) | 22.9 (9.1) |
| CD4 cell counts at ART initiation, median (IQR), cells/mL | 163 (62‐251) |
| CD4 cell counts at time of study, median (IQR), cells/mL | 479 (338‐656) |
| Changed ART regimen during follow‐up, No. (%) | 149 (28) |
| Duration on baseline regimen, median (IQR), ya | 2.4 (0.5‐3.3) |
| Participants initiated on protease inhibitors at ART initiation, No. (%) | 0 (0) |
| Participants taking protease inhibitors at time of study, No. (%) | 17 (3) |
| Participants initiated on stavudine at ART initiation, No. (%) | 87 (16) |
| Participants taking stavudine at time of study, No. (%) | 9 (2) |
Abbreviations: ART, antiretroviral therapy; BP, blood pressure; IQR, interquartile range; SD, standard deviation.
a
Among patients who had at least one change in drug regimen.
Twenty‐five participants were diagnosed with human immunodeficiency virus (HIV) during the study and had no HIV data and 28 had been diagnosed with HIV but were not receiving care during the ACHIEvA (Aging and Cardiovascular Diseases in HIV Patients of East Africa) study.